RECURRENT SMALL LYMPHOCYTIC LYMPHOMA

This early-stage study tests a new treatment for people with certain B-cell blood cancers (like lymphomas and leukemias) that have come back. The treatment involves taking a patient's own white blood cells, adding a new gene to help them find and kill cancer cells, and giving the…

This study tested a daily pill called ibrutinib in 154 people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL) that had come back or stopped responding to prior treatments. The goal was to see if the drug could c…

This study tests whether combining two targeted drugs, venetoclax and ibrutinib, can better control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It includes 234 patients whose cancer has returned or is hard to treat, as well as some untreated high-risk …

This study tests whether giving duvelisib on an irregular schedule can control chronic lymphocytic leukemia or small lymphocytic lymphoma as well as standard dosing, but with fewer severe side effects. Fifteen adults with cancer that returned or didn't respond to prior treatment …

This study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…

This early-phase study tests a new immune therapy for people with high-risk or returning non-Hodgkin lymphoma. After a stem cell transplant, patients receive specially modified T-cells designed to find and attack cancer cells. The main goal is to check safety and find the best do…

This study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…

This early-phase trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to recogniz…

This early-phase study tests a combination of three drugs (lenalidomide, ibrutinib, and rituximab) in 12 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatment. The main goal is to find the safest d…

This early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…

This study tests whether adding rituximab to ibrutinib works better than ibrutinib alone for patients with chronic lymphocytic leukemia (CLL) that has come back after treatment. About 66 adults with relapsed CLL or related blood cancers will receive either ibrutinib alone or ibru…